BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26966095)

  • 1. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
    Huang J; Campian JL; Gujar AD; Tran DD; Lockhart AC; DeWees TA; Tsien CI; Kim AH
    J Neurooncol; 2016 Jun; 128(2):259-66. PubMed ID: 26966095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
    Huang J; Campian JL; Gujar AD; Tsien C; Ansstas G; Tran DD; DeWees TA; Lockhart AC; Kim AH
    J Neurooncol; 2018 May; 138(1):105-111. PubMed ID: 29374809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
    Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
    Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
    McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
    J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
    Galanis E; Anderson SK; Miller CR; Sarkaria JN; Jaeckle K; Buckner JC; Ligon KL; Ballman KV; Moore DF; Nebozhyn M; Loboda A; Schiff D; Ahluwalia MS; Lee EQ; Gerstner ER; Lesser GJ; Prados M; Grossman SA; Cerhan J; Giannini C; Wen PY;
    Neuro Oncol; 2018 Mar; 20(4):546-556. PubMed ID: 29016887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
    Nghiemphu PL; Wen PY; Lamborn KR; Drappatz J; Robins HI; Fink K; Malkin MG; Lieberman FS; DeAngelis LM; Torres-Trejo A; Chang SM; Abrey L; Fine HA; Demopoulos A; Lassman AB; Kesari S; Mehta MP; Prados MD; Cloughesy TF;
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1422-7. PubMed ID: 20934264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
    Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
    Khasraw M; Lee A; McCowatt S; Kerestes Z; Buyse ME; Back M; Kichenadasse G; Ackland S; Wheeler H
    J Neurooncol; 2016 May; 128(1):163-171. PubMed ID: 26935578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
    Gilbert MR; Gonzalez J; Hunter K; Hess K; Giglio P; Chang E; Puduvalli V; Groves MD; Colman H; Conrad C; Levin V; Woo S; Mahajan A; de Groot J; Yung WK
    Neuro Oncol; 2010 Nov; 12(11):1167-72. PubMed ID: 20729242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma.
    Biau J; Thivat E; Chautard E; Stefan D; Boone M; Chauffert B; Bourgne C; Richard D; Molnar I; Levesque S; Bellini R; Kwiatkowski F; Karayan-Tapon L; Verrelle P; Godfraind C; Durando X
    Radiother Oncol; 2021 Jan; 154():227-234. PubMed ID: 32976869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
    Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
    Infante JR; Mendelson DS; Burris HA; Bendell JC; Tolcher AW; Gordon MS; Gillenwater HH; Arastu-Kapur S; Wong HL; Papadopoulos KP
    Invest New Drugs; 2016 Apr; 34(2):216-24. PubMed ID: 26924128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
    Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.